FDA ADE reports for human insulin by species (Dog vs Cat)

human insulin — FDA Animal & Veterinary ADE Reports by Species (Dog vs Cat)

Source: openFDA animalandveterinary/event.json, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-08-16. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. "Serious" follows the FDA serious_ae flag. Species values are as filed in each report. The Dog and Cat figures below are subsets of this drug's overall report total and do not necessarily sum to it (other species and reports with no species listed are excluded).

Dog (1292 reports)

• Serious adverse events (FDA serious_ae flag): 209 (16.2% of 1292)
• Top reported reactions (VEDDRA terms):
• Vomiting 197
• Lethargy (see also Central nervous system depression in 'Neurological') 144
• Lack of efficacy - NOS 139
• Hypoglycaemia 98
• Decreased appetite 94

Cat (1919 reports)

• Serious adverse events (FDA serious_ae flag): 621 (32.4% of 1919)
• Top reported reactions (VEDDRA terms):
• INEFFECTIVE, GLYCEMIC CONTROL 785
• Lack of efficacy - NOS 394
• Hypoglycaemia 358
• INEFFECTIVE, LOSS OF EFFECT 177
• Vomiting 157

Honest scope note

This topic is a species cross-section of an existing per-drug ADE topic. Figures are aggregates of spontaneously reported adverse events and reflect reporting volume, not incidence or risk per animal treated. "Lack of efficacy" and similar terms denote product-performance reports, not adverse reactions. Source JSON: pdf-raw/ade/ade_species_slice_2026-08-16.json (openFDA animalandveterinary/event.json, pulled 2026-08-16).